Tvardi Therapeutics Announces Ulcerative Colitis as Initial Indication for TTI-109

What Happened

• On July 30, 2026, Tvardi Therapeutics, Inc. (TVRD) filed a Current Report on Form 8‑K (Item 7.01) disclosing that it has selected ulcerative colitis as the initial indication for its clinical-stage candidate TTI-109. The company issued a press release titled “Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109” and made an updated corporate presentation publicly available; the press release and presentation are attached to the 8‑K as Exhibits 99.1 and 99.2.

Key Details

• Filing date: July 30, 2026 (Form 8‑K, Item 7.01, Regulation FD disclosure).
• Press release title: “Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109” (Exhibit 99.1).
• Updated corporate presentation posted the same day (Exhibit 99.2).
• The 8‑K is a disclosure under Regulation FD; it does not report earnings, executive changes, or other financial results.

Why It Matters

• The selection of ulcerative colitis establishes the company’s near-term clinical and development focus for TTI-109, which can drive upcoming milestones (trial starts, data readouts, partnerships) that influence TVRD’s valuation.
• Retail investors should review the attached press release and presentation for details on clinical plans, timelines, or strategic rationale; future filings or company announcements may disclose trial designs, enrollment targets, or regulatory milestones tied to this decision.